DK1951674T3 - Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser - Google Patents

Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser

Info

Publication number: DK1951674T3
Authority: DK; Denmark
Prior art keywords: sulfonamide derivatives; diseases; metalloproteinases; modulation; fibrosis
Prior art date: 2005-10-26

Application number

DK06807508.4T

Other languages

English (en)

Inventor

Patrick Gerber

Dominique Swinnen

Agnes Bombrun

Original Assignee

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2006-10-24

Publication date

2012-01-02

2006-10-24 Application filed by Merck Serono Sa filed Critical Merck Serono Sa

2012-01-02 Application granted granted Critical

2012-01-02 Publication of DK1951674T3 publication Critical patent/DK1951674T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Hematology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Pain & Pain Management (AREA)

DK06807508.4T 2005-10-26 2006-10-24 Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser DK1951674T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73040405P	2005-10-26	2005-10-26
EP05110035		2005-10-26
PCT/EP2006/067713 WO2007048788A1 (en)	2005-10-26	2006-10-24	Sulfonamide derivatives and use thereof for the modulation of metalloproteinases

Publications (1)

Publication Number	Publication Date
DK1951674T3 true DK1951674T3 (da)	2012-01-02

Family

ID=35695473

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06807508.4T DK1951674T3 (da)	2005-10-26	2006-10-24	Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser

Country Status (21)

Country	Link
US (1)	US7879876B2 (da)
EP (1)	EP1951674B1 (da)
JP (1)	JP5203956B2 (da)
KR (1)	KR20080064880A (da)
CN (1)	CN101346353B (da)
AT (1)	ATE534630T1 (da)
AU (1)	AU2006307939B2 (da)
BR (1)	BRPI0617931A2 (da)
CA (1)	CA2623879C (da)
CY (1)	CY1112370T1 (da)
DK (1)	DK1951674T3 (da)
EA (1)	EA013907B1 (da)
ES (1)	ES2372866T3 (da)
HR (1)	HRP20110874T1 (da)
IL (1)	IL190835A (da)
PL (1)	PL1951674T3 (da)
PT (1)	PT1951674E (da)
RS (1)	RS52229B (da)
SI (1)	SI1951674T1 (da)
WO (1)	WO2007048788A1 (da)
ZA (1)	ZA200803327B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101119969B (zh)	2004-07-15	2014-04-09	阿尔巴尼分子研究公司	芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CN102595902B (zh)	2009-05-12	2015-04-29	阿尔巴尼分子研究公司	7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
MX2011011900A (es)	2009-05-12	2012-01-20	Squibb Bristol Myers Co	Formas cristalinas de (s)-7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4 -(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y usos de las misma.
WO2010132437A1 (en)	2009-05-12	2010-11-18	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
HUE026406T2 (en) *	2009-06-19	2016-06-28	Teva Pharma	Treatment of multiple sclerosis with laquinimod
CN105616410A (zh) *	2009-07-30	2016-06-01	泰华制药工业有限公司	利用拉喹莫德治疗克隆氏病
ES2731052T3 (es)	2009-08-10	2019-11-13	Active Biotech Ab	Tratamiento de la enfermedad de Huntington usando laquinimod
WO2011109531A1 (en) *	2010-03-03	2011-09-09	Teva Pharmaceutical Industries Ltd.	Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
KR20150135552A (ko) *	2010-03-03	2015-12-02	테바 파마슈티컬 인더스트리즈 리미티드	라퀴니모드를 이용한 루푸스 신장염의 치료
SG183515A1 (en) *	2010-03-03	2012-10-30	Teva Pharma	Treatment of lupus arthritis using laquinimod
JP5950428B2 (ja) *	2010-08-05	2016-07-13	日東電工株式会社	線維化組織から正常組織を再生するための組成物
AU2011303013B2 (en) *	2010-09-17	2014-08-21	Kaken Pharmaceutical Co., Ltd.	Composition for maintaining platelet function
SG11201401330YA (en)	2011-10-12	2014-05-29	Teva Pharma	Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US20140323550A1 (en) *	2011-11-18	2014-10-30	Nitto Denko Corporation	Intestinal fibrosis treatment agent
US9161935B2 (en)	2012-02-03	2015-10-20	Teva Pharmaceutical Industries, Ltd.	Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
CN103102304B (zh) *	2013-01-19	2015-03-11	安徽师范大学	N-磺酰基取代四氢异喹啉衍生物的制备方法
WO2023147063A2 (en) *	2022-01-28	2023-08-03	Opna Bio SA	Compounds and methods for yap/tead modulation and indications therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9919776D0 (en) *	1998-08-31	1999-10-27	Zeneca Ltd	Compoujnds
ES2281346T3 (es) *	1999-06-04	2007-10-01	Astrazeneca Ab	Inhibidores de metaloproteinasas.
US6506773B2 (en)	2000-05-15	2003-01-14	Darwin Discovery Ltd.	Hydroxamic and carboxylic acid derivatives
GB0216383D0 (en) *	2002-07-13	2002-08-21	Astrazeneca Ab	Compounds
SE0301922D0 (sv) *	2003-06-27	2003-06-27	Astrazeneca Ab	Novel compounds

2006
- 2006-10-24 AT AT06807508T patent/ATE534630T1/de active
- 2006-10-24 RS RS20120059A patent/RS52229B/sr unknown
- 2006-10-24 CA CA2623879A patent/CA2623879C/en not_active Expired - Fee Related
- 2006-10-24 ES ES06807508T patent/ES2372866T3/es active Active
- 2006-10-24 KR KR1020087012135A patent/KR20080064880A/ko not_active Ceased
- 2006-10-24 US US12/091,582 patent/US7879876B2/en not_active Expired - Fee Related
- 2006-10-24 EA EA200801183A patent/EA013907B1/ru not_active IP Right Cessation
- 2006-10-24 JP JP2008537083A patent/JP5203956B2/ja not_active Expired - Fee Related
- 2006-10-24 WO PCT/EP2006/067713 patent/WO2007048788A1/en not_active Ceased
- 2006-10-24 PL PL06807508T patent/PL1951674T3/pl unknown
- 2006-10-24 PT PT06807508T patent/PT1951674E/pt unknown
- 2006-10-24 BR BRPI0617931-2A patent/BRPI0617931A2/pt not_active IP Right Cessation
- 2006-10-24 HR HR20110874T patent/HRP20110874T1/hr unknown
- 2006-10-24 CN CN2006800490790A patent/CN101346353B/zh not_active Expired - Fee Related
- 2006-10-24 AU AU2006307939A patent/AU2006307939B2/en not_active Ceased
- 2006-10-24 ZA ZA200803327A patent/ZA200803327B/xx unknown
- 2006-10-24 SI SI200631208T patent/SI1951674T1/sl unknown
- 2006-10-24 EP EP06807508A patent/EP1951674B1/en active Active
- 2006-10-24 DK DK06807508.4T patent/DK1951674T3/da active
2008
- 2008-04-14 IL IL190835A patent/IL190835A/en not_active IP Right Cessation
2012
- 2012-02-17 CY CY20121100170T patent/CY1112370T1/el unknown

Also Published As

Publication number	Publication date
IL190835A0 (en)	2008-11-03
AU2006307939B2 (en)	2012-03-29
CY1112370T1 (el)	2015-12-09
JP5203956B2 (ja)	2013-06-05
CA2623879A1 (en)	2007-05-03
BRPI0617931A2 (pt)	2011-08-09
SI1951674T1 (sl)	2012-01-31
PT1951674E (pt)	2011-12-19
CA2623879C (en)	2014-03-25
ZA200803327B (en)	2009-09-30
HRP20110874T1 (hr)	2011-12-31
ATE534630T1 (de)	2011-12-15
US7879876B2 (en)	2011-02-01
PL1951674T3 (pl)	2012-04-30
EP1951674A1 (en)	2008-08-06
HK1123304A1 (en)	2009-06-12
EA013907B1 (ru)	2010-08-30
EP1951674B1 (en)	2011-11-23
AU2006307939A1 (en)	2007-05-03
ES2372866T3 (es)	2012-01-27
IL190835A (en)	2013-01-31
WO2007048788A1 (en)	2007-05-03
JP2009513601A (ja)	2009-04-02
CN101346353B (zh)	2012-01-11
KR20080064880A (ko)	2008-07-09
US20090221575A1 (en)	2009-09-03
RS52229B (sr)	2012-10-31
CN101346353A (zh)	2009-01-14
EA200801183A1 (ru)	2008-10-30

Publication	Publication Date	Title
CY1112370T1 (el)	2015-12-09	Παραγωγα σουλφοναμιδης και χρηση αυτων στη ρυθμιση των μεταλλοπρωτεϊνασων
NO20070994L (no)	2007-04-26	N-hydroksamid derivater og anvendelse derav
EA201291273A1 (ru)	2013-06-28	Ингибиторы киназ, регулирующих апоптозный сигнал
EA200601868A1 (ru)	2007-04-27	3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов
EA200601141A1 (ru)	2007-02-27	Сульфонамидные производные для лечения заболеваний
EA200601223A1 (ru)	2006-12-29	Производные сульфонамида для лечения заболеваний
UA93213C2 (en)	2011-01-25	Pyrimidine amide compounds as pgds inhibitors
WO2010042649A3 (en)	2010-11-18	PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
IL184538A0 (en)	2007-10-31	N-hydroxyamide derivatives and use thereof
DK1828160T3 (da)	2012-02-13	Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere
NO20070820L (no)	2007-02-13	Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
CY1112088T1 (el)	2015-11-04	Παραγωγα ν-υδροξυαμιδης και η χρηση τους
EA200800342A1 (ru)	2008-08-29	ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
UA88785C2 (en)	2009-11-25	N-hydroxyamide derivatives and use thereof
CY1112367T1 (el)	2015-12-09	Κυκλικα παραγωγα σουλφονυλ αμινο και χρηση αυτων ως μμρ αναστολεων
UA84748C2 (ru)	2008-11-25	3- или 4-монозамещенные фенол и тиофенолпроизводные, полезные как н3 лиганды